Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 389-400

  Jochems, Jeanine ^a   Boulden, Janette ^a   Lee, Bridgin G ^a   Blendy, Julie A ^a   Jarpe, Matthew ^b   Mazitschek, Ralph ^c   Van Duzer, John H ^b   Jones, Simon ^b   Berton, Olivier ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Acetylon Pharmaceuticals   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antidepressant; depression; epigenetic; HDAC inhibitor; HDAC6; tubulin acetylation

Indexed keywords

2 ((1 (3 FLUOROPHENYL)CYCLOHEXYL)AMINO) N HYDROXYPYRIMIDINE 5 CARBOXAMIDE; ACY 738; ACY 775; ALPHA TUBULIN; ANTIDEPRESSANT AGENT; CITALOPRAM; ENTINOSTAT; FLUOXETINE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 2 (1 PHENYLCYCLOPROYLAMINO)PYRIMIDINE 5 CARBOXAMIDE; RICOLINOSTAT; TUBASTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; EXPLORATORY BEHAVIOR; HISTONE ACETYLATION; IC 50; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; CELL LINE, TRANSFORMED; EXPLORATORY BEHAVIOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84890546642     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.207     Document Type: Article

References (55)

1. Albelda N, Joel D (2012). Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci Biobehav Rev 36: 47-63.
2. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW (2012). Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3\+ regulatory T cell function through shared and isoformspecific mechanisms. Sci Signaling 5: ra45-ra45.
3. Benner L, Kalin JH, Kozikowski AP, Gordon MN, Morgan D SM-L B (2012). Selective HDAC6 inhibition decreases tau levels and improves spatial memory deficits in the rtg4510 mouse model. Society Neurosc 2012, Program No. 150.04 http://www. abstractsonline.com/Plan/ViewAbstract.aspx?sKey=804c6b94-1e77 49c4-80c5-4098b4c64f01&cKey=440038d9-3320-4f02-916d-7e5c2 4968839&mKey={70007181-01C9-4DE9-A0A2-EEBFA14CD9F1}.
4. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W Russo SJ et al (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
5. Bertrand P (2010). Inside HDAC with HDAC inhibitors. Eur J Med Chem 45: 2095-2116.
6. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ Warnow T et al (2010). Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6: 238-243.
7. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002). Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71: 667-680.
8. Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL (1986). Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126: 223-229.
9. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP (2010). Rational design and simple chemistry yield a superior neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132: 10842-10846.
10. Chen S, Owens GC, Makarenkova H, Edelman DB (2010). HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 5: e10848.
11. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M,Walther TC et al (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
12. Covington HE,Maze I, Laplant QC, Vialou VF, Ohnishi YN, Berton O et al (2009). Antidepressant actions of histone deacetylase inhibitors. J Neurosci 29: 11451-11460.
13. Covington HE, Vialou VF, Laplant Q, Ohnishi YN, Nestler EJ (2011). Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett 493: 122-126.
14. d'Ydewalle C, Bogaert E, Van Den Bosch L (2012) HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic, 13, 771-779.
15. d'Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J Kozikowski AP et al (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot Marie-Tooth disease. Nat Med 17 968-974.
16. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al (2011). Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(\+) T-regulatory cells. Mol Cell Biol 31: 2066-2078.
17. Ding H, Dolan PJ, Johnson GVW (2008). Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106: 2119-2130.
18. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ Humbert S et al (2007). Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27: 3571-3583.
19. Espallergues J, Teegarden SL, Veerakumar A, Boulden J, Challis C Jochems J et al (2012). HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci 32: 4400-4416.
20. Fukada M, Hanai A, Nakayama A, Suzuki T, Miyata N Rodriguiz RM et al (2012). Loss of deacetylation activity of HDAC6 affects emotional behavior in Mice. PLoS One 7: e30924.
21. Golden SA, Christoffel DJ, Heshmati M, Hodes GE, Magida J, Davis K et al (2013). Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med 19: 337-344.
22. Golden SA, Covington HE, Berton O, Russo SJ (2011). A standardized protocol for repeated social defeat stress in mice. Nat Protocols 6: 1183-1191.
23. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schlüter OM Bradke F et al (2012). Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 5: 52-63.
24. Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N Gao J et al (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
25. Gundersen BB, Blendy JA (2009). Neuropharmacology. Neuropharmacology 57: 67-74.
26. Haberland M, Montgomery RL, Olson EN (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
27. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389-4394.
28. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K et al (2010). Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatric Res 44: 263-270.
29. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
30. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
31. Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E et al (2013). Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation. Nat Neurosci 16: 434-440.
32. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL et al (2012). HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 7: e42983.
33. Kovacs JJ, Murphy PJM, Gaillard S, Zhao X, Wu J-T, Nicchitta CV et al (2005). HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
34. Lee JB, Wei J, Liu W, Cheng J, Feng J, Yan Z (2012). Histone deacetylase 6 gates the synaptic action of acute stress in prefrontal cortex. J Physiol 590: 1535-1546.
35. Li Y, Zhang X, Polakiewicz RD, Yao T-P, Comb MJ (2008). HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 283: 12686-12690.
36. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacologia 92: 180-185.
37. Lucki I, Dalvi A, Mayorga A (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155: 315-322.
38. Mao X, Hou T, Cao B, WangW, Li Z, Chen S et al (2011). The tricyclic anti-depressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol 79: 672-680.
39. Merali Z, Levac C, Anisman H (2003). Validation of a simple ethologically relevant paradigm for assessing anxiety in mice. BPS 54: 552-565.
40. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F et al (2013). L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110: 4804-4809.
41. Nishioka CC, Ikezoe TT, Yang JJ, Takeuchi SS, Koeffler HPH Yokoyama AA (2008). MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 32: 11.
42. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
43. Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG et al (2013). Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I/II study. Abstracts of the 54th Annual meeting of the American Society of Hematology. Atlanta, Georgia, 2012. Available online here https://ash.confex.com/ash/2012/webprogram/Paper52013.html.
44. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA McLaughlin K et al (2009). HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106: 19599-19604.
45. Russo SJ, Charney DS (2013). Next generation antidepressants. Proc Natl Acad Sci USA 110: 4441-4442.
46. Santo L, Hideshima T, Kung AL, Tseng J-C, Tamang D, Yang M et al (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119: 2579-2589.
47. Sung YM, Lee T, Yoon H, DiBattista AM, Song JM, Sohn Y et al (2013). Mercaptoacetamide-based class II HDAC inhibitor lowers Ab levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol 239: 192-201.
48. Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M et al (2000). Active maintenance of mHDA2/mHDAC6 histonedeacetylase in the cytoplasm. Curr Biol 10: 747-749.
49. Vishwakarma S, Iyer LR, Muley M, Singh PK, Shastry A, Saxena A et al (2013). Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. Int Immunopharmacol 16: 1-7.
50. White LA, Eaton MJ, Castro MC, Klose KJ, Globus MY, Shaw G et al (1994). Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons. J Neurosci 14: 6744-6753.
51. Xiong Y, Zhao K, Wu J, Xu Z, Jin S, Zhang YQ (2013). HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc Natl Acad Sci USA 110: 4604-4609.
52. Zhang L, Rubins NE, Ahima RS, Greenbaum LE, Kaestner KH (2005). Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab 2: 141-148.
53. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J et al (2007). HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27: 197-213.
54. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S Kneissel M et al (2008). Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28: 1688-1701.
55. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S et al (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22: 1168-1179.